Laura Sena is an Oncology physician affiliated with Johns Hopkins University. OpenAlex indexes 173 publications with 7,037 citations (h-index 17); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1650 Orleans St # 186
Baltimore, MD 212870013
Telephone
410-955-2817Provider last certified this registry record 11 Feb 2020.
Clinical trials
- 7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
59.5%Cytochrome P450 17A1 Inhibitor32.1%Abiraterone Acetate100%Part D≥11 patientsAndrogen Receptor Inhibitor15.6%Xtandi100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
30.9%Corticosteroid30.9%Prednisone100%Part D≥14 patientsNervous system
5.3%Opioid Agonist5.3%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- Synthetic lethal metabolic drug combinations for castration-resistant prostate cancer
Johns Hopkins University
FY2026$219,240K08CA273167 - Synthetic lethal metabolic drug combinations for castration-resistant prostate cancer
Johns Hopkins University
FY2025$219,240K08CA273167 - A study of IDH1-mutant prostate cancer to identify novel therapeutic targets
Johns Hopkins University
FY2024$421,042R21CA292179
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Daniel Laheru, MD
Johns Hopkins University
Demosthenes G. Katritsis
Johns Hopkins University
Tanguy Seiwert, MD
Johns Hopkins University
Evan Lipson, MD
Johns Hopkins University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”